A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: limits (518), restrictions (110), confines (20)

ACCORD-2 example sub-protocol

Description
CONFIDENTIAL ACCORD-2-002 - Sub protocol for Bemcentinib (Amendment 01) TITLE PAGE Master Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase
Url
/Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-example-sub-protocol.pdf

Form 034 Research Sponsorship Intention to Apply Form v3 Aug 2024 Clean

Description
Research Sponsorship Intention to Apply Form Please complete the information below as fully as possible. Section 1 – Applicant Details Title/Nam
Url
/Media/Southampton-Clinical-Research/Grants/Download/Form-034-Research-Sponsorship-Intention-to-Apply-Form-v3-Aug-2024-Clean.docx

Finance and Performance Reports 2023-24 Month 6 September 2023

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Finance Report 2023-24 Month 6 12.3 Ian Howard –
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-6-September-2023.pdf

Avelumab-Axitinib

Description
Chemotherapy Protocol RENAL CELL AVELUMAB-AXITINIB Regimen • Renal Cell - Avelumab-Axitinib Indication • Unresectable locally advanced or metastatic renal cell carcinoma (RCC
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Axitinib-Avelumab.pdf

Finance and Performance Reports 2022-23 Month 2 May 2022

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Issue to be addressed: Finance Report 2022-23 Mon
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Finance-and-Performance-Reports-2022-23-Month-2-May-2022.pdf

Dacomitinib

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) DACOMITINIB Regimen • NSCLC - Dacomitinib Indication Dacomitinib for untreated EGFR-positive non-small-cell
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Dacomitinib.pdf

BRC NMAHP researcher initiation internship award checklist 2023

Description
Name: Proposed Project Title: Contact details: Criteria Email: Mobile: 1. Registration with an appropriate UK regulatory and professional body: Evidence submitted
Url
/Media/Southampton-Clinical-Research/Downloads/BRC-NMAHP-researcher-initiation-internship-award-checklist-2023.pdf

Finance and Performance Reports 2020-21 Month 4 July 2020

Description
2020/21 Finance Report - Month 4 Report to: Board of Directors and Finance & Investment Committee August 2020 Title: Finance
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2020/finance-and-performance-reports-2020-21-month-4-july-2020-1.pdf

Papers Trust Board - 30 January 2020

Description
Date Time Location Chair Apologies Agenda Trust Board – Open Session 30/01/2020 9:00 - 11:45 Conference Room, Heartbeat Educa
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2020/Papers-Trust-Board-30-January-2020.pdf

mini-RCHOP 21

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE (mini-RCHOP 21) Regimen   Lymphoma – mini-RCHOP (21)-Cyclophosphamide-Doxorubicin-PrednisoloneRituximab-Vincristine Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/mini-RCHOP-21.pdf
61 to 70 of 518
Previous … 5 6 7 8 9 … Next